Reference number(s)
2602-H

Specialty Quantity Limit
Olumiant

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Olumiant	baricitinib

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Olumiant (baricitinib) 1 mg tablet	30 tablets per 30 days
Olumiant (baricitinib) 2 mg tablet	30 tablets per 30 days
Olumiant (baricitinib) 4 mg tablet	30 tablets per 30 days

FDA-recommended Dosing

Rheumatoid arthritis (adult)

2 mg once daily

- Reduce dose to 1 mg once daily for moderate renal impairment

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- Not recommended for severe renal impairment
- Co-administration with strong organic anion transporter (OAT3) inhibitors (e.g., probenecid)
  - If the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily
  - If the recommended dosage is 1 mg once daily, consider discontinuing concomitant strong OAT3 inhibitor

Alopecia areata (adults and pediatric patients 12 years of age and older)

2 mg once daily

- Increase to 4 mg once daily if the response to treatment is not adequate
- For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily
- Reduce the dose to 2 mg once daily when an adequate response has been achieved
- For moderate renal impairment, reduce to 1 mg once daily if the recommended dosage is 2 mg once daily and reduce to 2 mg once daily if the recommended dosage is 4 mg once daily
- Not recommended for severe renal impairment
- Co-administration with strong organic anion transporter (OAT3) inhibitors (e.g., probenecid)
  - If the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily
  - If the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily
  - If the recommended dosage is 1 mg once daily, consider discontinuing concomitant strong OAT3 inhibitor

Note: The criteria outlined in this policy is only applicable to coverage in the outpatient setting. Hospitalized members receiving Olumiant for the treatment of coronavirus disease 2019 (COVID-19) will be managed according to the member's inpatient benefit.

References

1. Olumiant [package insert]. Indianapolis, IN: Lilly USA, LLC; September 2026.

© 2026 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.